TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 and ≤ 75 years old with de novo diagnosis of AML or high-risk myelodysplastic syndrom for whom intensive induction chemotherapy is anticipated within 10 days after admission~* Patients willing to donate stool samples and to follow protocol recommendations~* Signature of informed and written consent~Exclusion Criteria:~* Acute promyelocytic leukemia (AML-M3)~* Known allergy or intolerance to trehalose or maltodextrin~* Pregnancy: positive urinary or blood test in female of childbearing potential~* Severe disease with a life expectancy \< 3 months~* Other ongoing interventional protocol that might interfere with the study~* Non eligibility for collection of autologous stools upon admission:~  * Patients refusing to consent~ * Antibiotherapy at the time of study inclusion ≥ 4 days~ * Concomitant or previous diagnosis of a significant inflammatory bowel disease (UC, CD) or other progressive digestive disease requesting treatment or further medical exploration~ * Presence of severe colitis of any etiology at the time of admission or severe digestive disorders (acute or chronic diarrhea) within 3 months preceding inclusion~ * Patient getting a recent colonoscopy (within 3 months preceding inclusion)~* Detection of MDRB, pathogenic bacteria, parasites, norovirus and/or rotavirus during screening of autologous stool collected at baseline~* Non eligibility for inoculum transplantation: persistent mucositis, colitis, or haemorrhoids, presence of blood in more than 50% of patient's faeces the week preceding the transplantation~* Non feasibility of inoculum procedure: patient refusal; technical or biological mismatch of the inoculum~* Absence of effective contraceptive method for female of childbearing potential~* Lactation~* Inability to give an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Autologous Fecal Microbiota Transplantation (Type: EXPERIMENTAL): Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants will have a contrast enhanced brain MRI which documents evidence of primary or metastatic brain tumor or suspected tumor recurrence after therapy~* Tumor size at least 1.5 cm in greatest axial dimension on MRI. MRI must be obtained within 2 months of study inclusion~* Adult patients 18 or older~* Female patients must not be pregnant or breast feeding and both women of childbearing potential, and men, must use appropriate means of contraception and must be maintained for at least 45 days after injection of 124I-NM404 Participants must not attempt to become pregnant during this time~* Platelet count must be ≥ 160,000/µl, Hematocrit must be ≥ 22%, Leukocyte count must be ≥ 3,000/µL, Creatinine must be ≤ 2.5 mg/dL, ALT must be ≤ 130 U/L, AST must be ≤ 100 U/L, and urine or serum pregnancy test must be negative for pregnancy~* Patient provides informed consent~* Karnofsky score ≥ 60~* For previously treated brain tumors, targeted brain therapy (radiation or drug) must have concluded ≥2 months prior to injection of 124I-NM404~Exclusion Criteria:~* Life expectancy of \< 3 months~* Allergy to potassium iodide (SSKI or Thyroshield)~* Unwilling or unable to complete 3 separate PET/CT imaging sessions of 90 minutes each over 3 days~* Pregnancy or breast-feeding during time of study and/or anticipated breast feeding at any time for 45 days after injection of 124I-NM404.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I124-NM404 brain metastases or GBM imaging (Type: EXPERIMENTAL): injection of I-124NM404 for imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients eligible for allogeneic HCT, independent of age~* Adult patients of any age with a cytopathologically confirmed diagnosis according to WHO classification of newly diagnosed AML (not APL = AML-M3), de novo AML or secondary AML~* in first complete remission (CR1)~* Poor risk or very poor risk subgroups~* WHO performance status ≤ 2~* Written informed consent~Exclusion Criteria:~* Patient not in CR1~* Patients who have senile dementia, mental impairment of any other psychiatric disorder that prohibits the patient from understanding and giving informed consent~* Active serious infections like HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV)~* Patient is unwilling to use contraceptive techniques during and for 12 months following treatment~* Female patient who is pregnant or breastfeeding~* Active and uncontrolled infections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria~1. Signed Informed Consent Form, prior to screening evaluations~2. In good physical and mental health~3. Pre-menopausal females between the ages of 21-37 years (both inclusive) at the time of randomisation~4. Infertility for at least 1 year before randomisation, except for proven bilateral tubal infertility~Exclusion Criteria~1. Any clinically significant systemic disease~2. Endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney)~3. History of recurrent miscarriage~4. Undiagnosed vaginal bleeding

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Daily Tablets Dosing
- 2 (Type: EXPERIMENTAL): Daily Tablets Dose
- 3 (Type: EXPERIMENTAL): Daily Tablets Dosing
- 4 (Type: EXPERIMENTAL): Daily Tablets Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female infants ≥2 months to ≤6 months at the time of consent.~* Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.~Exclusion Criteria:~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)~* Major known congenital malformation or serious chronic disorder.~* History of microbiologically proven invasive disease caused by S pneumoniae.~* Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- 20-valent pneumococcal conjugate vaccine (subcutaneous) (Type: EXPERIMENTAL): 20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
- 13-valent pneumococcal conjugate vaccine (subcutaneous) (Type: ACTIVE_COMPARATOR): 13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)
- 20-valent pneumococcal conjugate vaccine (intramuscular) (Type: EXPERIMENTAL): 20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Child and Adolescent Anxiety Disorders (CAMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for separation anxiety disorder, social phobia, or generalized anxiety disorder~Exclusion Criteria:~* Major neurological disorder or medical illness that would interfere with participation in the study

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Sertraline (Type: ACTIVE_COMPARATOR): Participants received sertraline for 12 weeks.
- CBT (Type: ACTIVE_COMPARATOR): Participants received cognitive behavioral therapy for 12 weeks
- SRT + CBT (Type: ACTIVE_COMPARATOR): Participants received both sertraline and CBT for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received a placebo pill for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Both man and woman who is over 19 years old~* Patient with dyslipidemia and hypertension~Exclusion Criteria:~* sSBP difference is ≥20 mmHg or sDBP difference is ≥10 mmHg~* A history of cardiovascular disease~* Rhabdomyolysis, myopathy~* Hypertension or hypercholesterolemia due to secondary causes~* Uncontrolled diabetes~* Evidence of hepatic or renal disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YHP1701 (Type: EXPERIMENTAL): PO, Once daily (QD), 8 weeks
- YHR1703 (Type: ACTIVE_COMPARATOR): PO, Once daily (QD), 8 weeks
- YHR1704 (Type: ACTIVE_COMPARATOR): PO, Once daily (QD), 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Electronic Cigarettes on Nicotine Concentrations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking 10 cigarettes daily~* Agree to abstain from smoking and use electronic cigarettes for 2 weeks~Exclusion Criteria:~* Unstable medical or psychiatric disorders as determined by the principal investigator~* Pregnancy~* Known hypersensitivity to nicotine or propylene glycol or menthol~* Recent M. I. or stroke~* Uncontrolled hypertension (BP.\>160/100)~* Insulin dependent diabetes~* Known COPD or asthma~* Alcohol or other drug abuse or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Tobacco Flavor/ Tobacco & Menthol Flavor (Type: OTHER): Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco \& Menthol Flavor (18mg/mL nicotine)
- Tobacco & Menthol Flavor/Tobacco Flavor (Type: OTHER): Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco \& Menthol Flavor (18mg/mL nicotine)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dapagliflozin (DAPA) Effects in HFpEF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study specific procedures.~* Male or female.~* Symptoms of dyspnea (NYHA II-III) with no non-cardiac or ischemia explanation.~* EF ≥ 50% + BMI ≥ 30 kg/m\^2~* Elevated pulmonary capillary wedge pressure (PCWP) during exercise (≥ 25 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized .~Exclusion Criteria:~* Type I diabetes.~* Type II diabetes with poor control (HgbA1C ≥ 10%).~* Recent hospitalization (\< 30 days) or revascularization (\< 90 days).~* Primary cardiomyopathy (such as amyloid).~* Constrictive pericarditis.~* Dyspnea due to primary lung disease or myocardial ischemia in the opinion of the investigator.~* Severe anemia (hemoglobin \< 9gm/dl.~* Significant left-sided valvular heart disease (\> mild stenosis, \> moderate regurgitation),~* Severe kidney disease (estimated glomerular filtration rate (GFR) \< 30) or liver disease,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin Group (Type: EXPERIMENTAL): Subjects with HFpEF will take the study drug dapagliflozin daily
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects with HFpEF will take a placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Has consented to participate in this study.~* Taking opioid therapy for persistent non-cancer pain.~* Has bowel dysfunction mainly due to opioids.~* Has bowel dysfunction since starting opioids as defined by infrequent bowel movements and additional bowel-related symptoms.~* Willing to discontinue laxative therapy (will be provided study-specific standardized laxative if needed).~* Willing to report daily bowel symptoms.~Exclusion criteria:~* Pregnant, lactating, or planning to become pregnant.~* Not ambulatory.~* Participated in another trial with an investigational drug in the past 30 days.~* Taking opioids for the management of drug addiction or cancer-related pain.~* Severe constipation whereby the subject is at immediate risk of developing serious complications of constipation.~* Gastrointestinal or pelvic disorders known to affect bowel transit, produce gastrointestinal (GI) obstruction, or contribute to bowel dysfunction.~* HIV-infected, has active hepatitis, or has ever been infected with hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Alvimopan 0.5 mg once daily (Type: EXPERIMENTAL): None
- alvimopan 0.5 mg twice daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methadone in Pediatric Anesthesiology II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria.~* Age 11-18 years~* Undergoing general anesthesia and idiopathic posterior spinal surgery with anticipated postop inpatient stay of \> 3 days~* Signed, written, informed consent from legal guardians and assent from patient~Exclusion Criteria.~* History of or known liver or kidney disease.~* Females who are pregnant or nursing.~* Children with developmental delay~* Children undergoing surgery for scoliosis of musculoskeletal origin

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- methadone HCl 0.3 mg/kg (Type: EXPERIMENTAL): 0.3mg/kg IV methadone HCl
- methadone HCl 0.4 mg/kg (Type: EXPERIMENTAL): 0.4mg/kg IV methadon HCl
- control group (Type: ACTIVE_COMPARATOR): control no methadone, standard of care opioids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Is male or female ≥5 years old~* If female of childbearing potential (including perimenopausal women who have had a menstrual period within one year):~  1. Not breastfeeding~ 2. Negative pregnancy test result~ 3. Must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire duration of the study (Double barrier methods including the use of female diaphragm and male condom with spermicide can also be used.)~* Has physician-confirmed lipodystrophy as defined by evidence of generalized (whole body) or partial (limbs) loss of body fat outside the range of normal variation~* Has been diagnosed with at least one of the following 2 metabolic disorders:~  1. Diabetes Mellitus~ 2. Hypertriglyceridemia as defined by fasting triglyceride concentrations \>200 mg/dL~* If ≥18 years of age, is able to read, understand, and sign the Informed Consent Form (ICF) and an Authorization to Use and Disclose Protected Health Information form, communicate with the investigator, and understand and comply with protocol requirements~* If \<18 years of age, has a parent or legal guardian to read and understand the ICF and Child Assent Form, communicate with the investigator, and understand and comply with protocol requirements. Adolescent subjects must also read and understand the Child Assent Form; if the child is too young or unable to read, then the Child Assent Form must be explained to the child.~Exclusion Criteria:~* Has been diagnosed with HIV infection~* Has known infectious liver disease~* Has known allergies to E. coli-derived proteins or hypersensitivity to any component of study treatment

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Claustrophobia and Patient Motion After Training of MRI Personnel in Comfort TalkTM

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Facilities performing MRI examinations~* Facilities capturing data on noncompletion of MRI scans~* Facilities willing to have their personnel trained~* Facilities with personnel interested and willing to be trained~* Facilities able to obtain IRB review~Exclusion Criteria:~* Facilities not performing MRI examinations~* Facilities not capturing data on noncompletion of MRI scans~* Facilities not willing to have their personnel trained~* Facilities unable to obtain IRB review

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Comfort Talk® Training (Type: EXPERIMENTAL): The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete